Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOTOX for Upper Facial Rhytides
NCT02261493Phase 3Completed
- Sponsor
- Allergan
- Start
- Oct 2014
- Primary completion
- Jun 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial of onabotulinumtoxinA in facial rhytides (3 arms), sponsored by Allergan. Primary endpoint: Percentage of Subjects With >=2-Grade Improvement From Baseline on Both the Investigator's and Subject's Facial Wrinkle Scale (FWS) Ratings of Forehead Line Severity at Maximum Eyebrow Elevation at Day 30. Started Oct 2014; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
facial rhytides
Beyond the preview
Go deeper on NCT02261493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02261493.